212 related articles for article (PubMed ID: 16730870)
1. Memantine augmentation for refractory obsessive-compulsive disorder.
Pasquini M; Biondi M
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1173-5. PubMed ID: 16730870
[TBL] [Abstract][Full Text] [Related]
2. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
Aboujaoude E; Barry JJ; Gamel N
J Clin Psychopharmacol; 2009 Feb; 29(1):51-5. PubMed ID: 19142108
[TBL] [Abstract][Full Text] [Related]
3. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).
Haghighi M; Jahangard L; Mohammad-Beigi H; Bajoghli H; Hafezian H; Rahimi A; Afshar H; Holsboer-Trachsler E; Brand S
Psychopharmacology (Berl); 2013 Aug; 228(4):633-40. PubMed ID: 23525525
[TBL] [Abstract][Full Text] [Related]
4. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder.
Stewart SE; Jenike EA; Hezel DM; Stack DE; Dodman NH; Shuster L; Jenike MA
J Clin Psychopharmacol; 2010 Feb; 30(1):34-9. PubMed ID: 20075645
[TBL] [Abstract][Full Text] [Related]
5. Memantine for treatment-resistant OCD.
Poyurovsky M; Weizman R; Weizman A; Koran L
Am J Psychiatry; 2005 Nov; 162(11):2191-2. PubMed ID: 16263867
[No Abstract] [Full Text] [Related]
6. Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial.
Häge A; Banaschewski T; Buitelaar JK; Dijkhuizen RM; Franke B; Lythgoe DJ; Mechler K; Williams SC; Dittmann RW;
Trials; 2016 Mar; 17(1):141. PubMed ID: 26983548
[TBL] [Abstract][Full Text] [Related]
7. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
Feusner JD; Kerwin L; Saxena S; Bystritsky A
Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653
[TBL] [Abstract][Full Text] [Related]
8. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
Askari S; Mokhtari S; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
BMC Psychiatry; 2022 Jan; 22(1):34. PubMed ID: 35022014
[TBL] [Abstract][Full Text] [Related]
9. Memantine Augmentation in a Down's Syndrome Adolescent with Treatment- Resistant Obsessive-Compulsive Disorder.
Pekrul SR; Fitzgerald KD
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):593-5. PubMed ID: 26258664
[No Abstract] [Full Text] [Related]
10. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
Lafleur DL; Pittenger C; Kelmendi B; Gardner T; Wasylink S; Malison RT; Sanacora G; Krystal JH; Coric V
Psychopharmacology (Berl); 2006 Jan; 184(2):254-6. PubMed ID: 16374600
[TBL] [Abstract][Full Text] [Related]
11. Combination Therapy of Serotonin Reuptake Inhibitors and Memantine for Obsessive- Compulsive Disorder: A Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
Kishi T; Matsuda Y; Iwata N
J Alzheimers Dis; 2018; 64(1):43-48. PubMed ID: 29865079
[TBL] [Abstract][Full Text] [Related]
12. A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder.
Modarresi A; Chaibakhsh S; Koulaeinejad N; Koupaei SR
Psychiatry Res; 2019 Dec; 282():112602. PubMed ID: 31630042
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive-compulsive disorder: A network meta-analysis.
Maiti R; Mishra A; Srinivasan A; Mishra BR
Acta Psychiatr Scand; 2023 Jul; 148(1):19-31. PubMed ID: 37177823
[TBL] [Abstract][Full Text] [Related]
14. Memantine for posttraumatic stress disorder in an older veteran.
Chopra MP; Trevino KM; Kowall NW
J Clin Psychopharmacol; 2011 Dec; 31(6):787-8. PubMed ID: 22051925
[No Abstract] [Full Text] [Related]
15. Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Randomized Controlled Trial.
Modarresi A; Sayyah M; Razooghi S; Eslami K; Javadi M; Kouti L
Pharmacopsychiatry; 2018 Nov; 51(6):263-269. PubMed ID: 29100251
[TBL] [Abstract][Full Text] [Related]
16. Augmentation With Memantine in Obsessive-Compulsive Disorder.
Andrade C
J Clin Psychiatry; 2019 Dec; 80(6):. PubMed ID: 31846244
[TBL] [Abstract][Full Text] [Related]
17. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
Saxena S; Wang D; Bystritsky A; Baxter LR
J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572
[TBL] [Abstract][Full Text] [Related]
18. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder.
Berlin HA; Koran LM; Jenike MA; Shapira NA; Chaplin W; Pallanti S; Hollander E
J Clin Psychiatry; 2011 May; 72(5):716-21. PubMed ID: 20816027
[TBL] [Abstract][Full Text] [Related]
19. Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs-an open-label study.
Stryjer R; Budnik D; Ebert T; Green T; Polak L; Weizman S; Spivak B
Clin Neuropharmacol; 2014; 37(3):79-81. PubMed ID: 24824662
[TBL] [Abstract][Full Text] [Related]
20. Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trial.
Seedat S; Stein DJ
Int Clin Psychopharmacol; 1999 Nov; 14(6):353-6. PubMed ID: 10565802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
